Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 136
Filtrar
1.
Front Immunol ; 15: 1363457, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38855111

RESUMEN

Introduction: Human infections with the food-borne enteropathogen Campylobacter jejuni are responsible for increasing incidences of acute campylobacteriosis cases worldwide. Since antibiotic treatment is usually not indicated and the severity of the enteritis directly correlates with the risk of developing serious autoimmune disease later-on, novel antibiotics-independent intervention strategies with non-toxic compounds to ameliorate and even prevent campylobacteriosis are utmost wanted. Given its known pleiotropic health-promoting properties, curcumin constitutes such a promising candidate molecule. In our actual preclinical placebo-controlled intervention trial, we tested the anti-microbial and anti-inflammatory effects of oral curcumin pretreatment during acute experimental campylobacteriosis. Methods: Therefore, secondary abiotic IL-10-/- mice were challenged with synthetic curcumin via the drinking water starting a week prior oral C. jejuni infection. To assess anti-pathogenic, clinical, immune-modulatory, and functional effects of curcumin prophylaxis, gastrointestinal C. jejuni bacteria were cultured, clinical signs and colonic histopathological changes quantitated, pro-inflammatory immune cell responses determined by in situ immunohistochemistry and intestinal, extra-intestinal and systemic pro-inflammatory mediator measurements, and finally, intestinal epithelial barrier function tested by electrophysiological resistance analysis of colonic ex vivo biopsies in the Ussing chamber. Results and discussion: Whereas placebo counterparts were suffering from severe enterocolitis characterized by wasting symptoms and bloody diarrhea on day 6 post-infection, curcumin pretreated mice, however, were clinically far less compromised and displayed less severe microscopic inflammatory sequelae such as histopathological changes and epithelial cell apoptosis in the colon. In addition, curcumin pretreatment could mitigate pro-inflammatory innate and adaptive immune responses in the intestinal tract and importantly, rescue colonic epithelial barrier integrity upon C. jejuni infection. Remarkably, the disease-mitigating effects of exogenous curcumin was also observed in organs beyond the infected intestines and strikingly, even systemically given basal hepatic, renal, and serum concentrations of pro-inflammatory mediators measured in curcumin pretreated mice on day 6 post-infection. In conclusion, the anti-Campylobacter and disease-mitigating including anti-inflammatory effects upon oral curcumin application observed here highlight the polyphenolic compound as a promising antibiotics-independent option for the prevention from severe acute campylobacteriosis and its potential post-infectious complications.


Asunto(s)
Infecciones por Campylobacter , Campylobacter jejuni , Curcumina , Animales , Curcumina/administración & dosificación , Curcumina/farmacología , Infecciones por Campylobacter/tratamiento farmacológico , Infecciones por Campylobacter/inmunología , Ratones , Campylobacter jejuni/efectos de los fármacos , Administración Oral , Ratones Noqueados , Modelos Animales de Enfermedad , Ratones Endogámicos C57BL , Interleucina-10/metabolismo , Enfermedad Aguda , Antibacterianos/administración & dosificación
2.
Antimicrob Agents Chemother ; : e0027223, 2023 06 26.
Artículo en Inglés | MEDLINE | ID: mdl-37358413

RESUMEN

Campylobacter bacteremia is an uncommon disease that mainly occurs in immunocompromised patients and is associated with antibiotic resistance, particularly in Campylobacter coli. We report a patient with persistent blood infection because of a multidrug-resistant (MDR) C. coli strain over a 3-month period. Through this period monotherapy with meropenem was associated with the development of resistance to it. Improving immunity status and a combined therapy for intestinal decolonization were useful to control persistent C. coli infection in this patient.


Asunto(s)
Bacteriemia , Infecciones por Campylobacter , Campylobacter coli , Neoplasias Hematológicas , Humanos , Meropenem/uso terapéutico , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Infecciones por Campylobacter/complicaciones , Infecciones por Campylobacter/tratamiento farmacológico , Neoplasias Hematológicas/tratamiento farmacológico , Bacteriemia/tratamiento farmacológico
3.
BMC Infect Dis ; 22(1): 700, 2022 Aug 20.
Artículo en Inglés | MEDLINE | ID: mdl-35987621

RESUMEN

BACKGROUND: Campylobacter jejuni is a common cause of acute gastroenteritis, but central nervous system infections are rare manifestations of Campylobacter infection. Therefore, C. jejuni trauma-related subdural hygroma infection in children is poorly described in the literature. CASE PRESENTATION: We described a 2-year old boy with lobar holoprosencephaly presenting with subdural hygroma following head trauma. C. jejuni infection was confirmed from a subdural hygroma sample by culture as well as by DNA sequencing of a broad range 16S rDNA PCR product. Cerebrospinal fluid from the ventriculoperitoneal shunt remained sterile. Combined neurosurgical and antimicrobial treatment led to complete recovery. Review of the literature showed that the most common manifestation of Campylobacter central nervous system infection is meningitis, mostly in neonates, and subdural hygroma infection was described for only one case. CONCLUSIONS: Subdural hygroma infection caused by C. jejuni is a rare clinical condition in children. Molecular methods represent an important tool for the detection of rare or unexpected pathogens. No standard recommendations for antimicrobial treatment of C. jejuni subdural space infection in children are available, but meropenem treatment combined with surgery seems to be an effective approach.


Asunto(s)
Infecciones por Campylobacter , Campylobacter jejuni , Meningitis , Efusión Subdural , Infecciones por Campylobacter/complicaciones , Infecciones por Campylobacter/diagnóstico , Infecciones por Campylobacter/tratamiento farmacológico , Campylobacter jejuni/genética , Niño , Preescolar , Humanos , Recién Nacido , Masculino , Meningitis/complicaciones , Efusión Subdural/diagnóstico , Efusión Subdural/etiología , Efusión Subdural/cirugía , Espacio Subdural
4.
Eur J Clin Microbiol Infect Dis ; 41(5): 849-852, 2022 May.
Artículo en Inglés | MEDLINE | ID: mdl-35304678

RESUMEN

Ibrutinib is a Bruton tyrosine kinase (BTK) inhibitor used in B-cell lymphoproliferative disorders. Patients with genetic BTK deficiency are susceptible to recurrent and severe Campylobacter infections. We report 4 patients treated with ibrutinib who developed chronic or extra-digestive campylobacteriosis resembling ibrutinib-related adverse events including diarrhea (n = 4), panniculitis (n = 2), and arthritis (n = 1). Microbiological explorations identified Campylobacter jejuni (n = 3) or Campylobacter coli (n = 1). All the patients completely recovered after a short course of oral antibiotic therapy. In patients treated with ibrutinib presenting with chronic diarrhea, dermatological, or rheumatological manifestations, campylobacteriosis should be ruled out before attributing the symptoms to ibrutinib and discuss its discontinuation.


Asunto(s)
Infecciones por Campylobacter , Leucemia Linfocítica Crónica de Células B , Adenina/análogos & derivados , Agammaglobulinemia Tirosina Quinasa , Infecciones por Campylobacter/tratamiento farmacológico , Diarrea/tratamiento farmacológico , Humanos , Leucemia Linfocítica Crónica de Células B/inducido químicamente , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Leucemia Linfocítica Crónica de Células B/genética , Piperidinas , Inhibidores de Proteínas Quinasas , Pirazoles/efectos adversos , Pirimidinas/efectos adversos
5.
Clin Infect Dis ; 75(4): 702-709, 2022 09 10.
Artículo en Inglés | MEDLINE | ID: mdl-34849656

RESUMEN

BACKGROUND: Campylobacter spp. bacteremia is a severe infection. A nationwide 5-year retrospective study was conducted to characterize its clinical features and prognostic factors. METHODS: The study included patients with Campylobacter spp. bacteremia diagnosed in 37 French hospitals participating in the surveillance network of the National Reference Center for Campylobacters and Helicobacters, from 1 January 2015 to 31 December 2019. The goal was to analyze the effects of a delay of appropriate antibiotic therapy and other risk factors on 30-day mortality rates, antibiotic resistance, patient characteristics, and prognosis according to the Campylobacter species. RESULTS: Among the 592 patients, Campylobacter jejuni and Campylobacter fetus were the most commonly identified species (in 42.9% and 42.6%, respectively). The patients were elderly (median age 68 years), and most had underlying conditions, mainly immunodepression (43.4%), hematologic cancers (25.9%), solid neoplasms (23%), and diabetes (22.3%). C. jejuni and Campylobacter coli were associated with gastrointestinal signs, and C. fetus was associated with secondary localizations. Among the 80 patients (13.5%) with secondary localizations, 12 had endocarditis, 38 vascular, 24 osteoarticular, and 9 ascitic fluid infections. The 30-day mortality rate was 11.7%, and an appropriate antibiotic treatment was independently associated with 30-day survival (odds ratio, 0.47 [95% confidence interval, .24-.93]; P = .03). The median efficient therapy initiation delay was quite short (2 days [interquartile range, 0-4 days]) but it had no significant impact on the 30-day mortality rate (P = .78). CONCLUSIONS: Campylobacter spp. bacteremia mainly occurred in elderly immunocompromised individuals with variable clinical presentations according to the species involved. Appropriate antimicrobial therapy was associated with improved 30-day survival.


Asunto(s)
Bacteriemia , Infecciones por Campylobacter , Campylobacter jejuni , Campylobacter , Anciano , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Bacteriemia/diagnóstico , Bacteriemia/tratamiento farmacológico , Bacteriemia/epidemiología , Infecciones por Campylobacter/tratamiento farmacológico , Infecciones por Campylobacter/epidemiología , Humanos , Estudios Retrospectivos
6.
Biomolecules ; 13(1)2022 12 29.
Artículo en Inglés | MEDLINE | ID: mdl-36671455

RESUMEN

The progressively rising food-borne Campylobacter jejuni infections pose serious health problems and socioeconomic burdens. Given that antibiotic therapy is not recommended for most campylobacteriosis patients, novel treatment options include strategies targeting iron homeostasis that impacts both C. jejuni virulence and inflammatory cell damage caused by toxic oxygen species. In our preclinical intervention study, we tested potential disease-alleviating effects upon prophylactic oral application of the iron-chelating compound desferoxamine (DESF) in acute murine campylobacteriosis. Therefore, microbiota-depleted IL-10-/- mice received synthetic DESF via the drinking water starting seven days before oral infection with C. jejuni strain 81-176. Results revealed that the DESF application did not reduce gastrointestinal pathogen loads but significantly improved the clinical outcome of infected mice at day 6 post-infection. This was accompanied by less pronounced colonic epithelial cell apoptosis, attenuated accumulation of neutrophils in the infected large intestines and abolished intestinal IFN-γ and even systemic MCP-1 secretion. In conclusion, our study highlights the applied murine campylobacteriosis model as suitable for investigating the role of iron in C. jejuni infection in vivo as demonstrated by the disease-alleviating effects of specific iron binding by oral DESF application in acute C. jejuni induced enterocolitis.


Asunto(s)
Infecciones por Campylobacter , Campylobacter jejuni , Enterocolitis , Animales , Ratones , Deferoxamina/farmacología , Deferoxamina/uso terapéutico , Infecciones por Campylobacter/tratamiento farmacológico , Enterocolitis/tratamiento farmacológico , Intestinos
7.
Rev Chilena Infectol ; 38(3): 440-445, 2021 Jun.
Artículo en Español | MEDLINE | ID: mdl-34479303

RESUMEN

Infection is a rare complication of abdominal aortic aneurysms. Campylobacter fetus has special tropism for vascular endothelium. It has been reported as a cause of infected abdominal aortic aneurysms. The mortality of these patients is high, so an early recognition with a start of antibiotic therapy is crucial. In addition to medical treatment surgery may be required, which has high mortality in patients with many diseases and unstable. We report the case of an old man with infected abdominal aortic aneurysm with C. fetus, whom was decided to be treated with imipenem, due to his cardiovascular history and his general condition at admission. The patient showed a good clinical response without recurrence of symptoms. We also carry out a review of the reported cases.


Asunto(s)
Aneurisma Infectado , Aneurisma de la Aorta Abdominal , Infecciones por Campylobacter , Aneurisma Infectado/diagnóstico por imagen , Antibacterianos/uso terapéutico , Infecciones por Campylobacter/diagnóstico , Infecciones por Campylobacter/tratamiento farmacológico , Campylobacter fetus , Humanos , Masculino
8.
BMC Infect Dis ; 21(1): 680, 2021 Jul 13.
Artículo en Inglés | MEDLINE | ID: mdl-34256709

RESUMEN

BACKGROUND: Campylobacter fetus is an uncommon Campylobacter species, and its infections mainly cause infective endocarditis, aortic aneurysm, and meningitis rather than enteritis. It is more likely to be detected in blood than Campylobacter jejuni or Campylobacter coli, specifically reported in 53% of patients. In our case, C. fetus was detected in both blood and cerebrospinal fluid (CSF) cultures. CASE PRESENTATION: A 33-year-old woman, who was on maintenance chemotherapy for acute lymphoblastic leukemia (ALL), presented to our clinic with chief complaints of severe headache and nausea. Blood and CSF cultures revealed C. fetus. We administrated meropenem 2 g intravenously (IV) every 8 h for 3 weeks, and she was discharged without neurological sequelae. CONCLUSION: We encountered a case of C. fetus meningitis without gastrointestinal symptoms, neck stiffness or jolt accentuation in a patient with ALL. Undercooked beef was considered the source of C. fetus infection in this case, suggesting that the need for a neutropenic diet and safe food handling be considered.


Asunto(s)
Infecciones por Campylobacter , Campylobacter fetus/aislamiento & purificación , Ceftriaxona/administración & dosificación , Enfermedades Transmitidas por los Alimentos , Meningitis Bacterianas , Meropenem/administración & dosificación , Leucemia-Linfoma Linfoblástico de Células Precursoras , Adulto , Antibacterianos/administración & dosificación , Infecciones por Campylobacter/sangre , Infecciones por Campylobacter/líquido cefalorraquídeo , Infecciones por Campylobacter/diagnóstico , Infecciones por Campylobacter/tratamiento farmacológico , Diagnóstico Diferencial , Quimioterapia/métodos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Femenino , Enfermedades Transmitidas por los Alimentos/complicaciones , Enfermedades Transmitidas por los Alimentos/diagnóstico , Enfermedades Transmitidas por los Alimentos/tratamiento farmacológico , Enfermedades Transmitidas por los Alimentos/microbiología , Humanos , Meningitis Bacterianas/diagnóstico , Meningitis Bacterianas/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Resultado del Tratamiento
9.
Rev. chil. infectol ; 38(3): 440-445, jun. 2021. ilus, tab
Artículo en Español | LILACS | ID: biblio-1388249

RESUMEN

Resumen La infección es una complicación infrecuente de los aneurismas de la aorta abdominal. Campylobacter fetus tiene un especial tropismo por el endotelio vascular y ha sido reportado como causa de infección de aneurismas aórticos. Este tipo de infección es de alta mortalidad por lo que el reconocimiento temprano con el inicio precoz de terapia antibacteriana efectiva es clave. Además del tratamiento médico, puede requerirse cirugía, la que tiene una alta letalidad en pacientes inestables y con comorbilidades. Comunicamos el caso clínico de un adulto mayor con un aneurisma de aorta abdominal infectado por C. fetus. Dado su compromiso del estado general y antecedentes cardiovasculares se decidió tratamiento médico con imipenem, con una buena respuesta clínica y microbiológica, sin recurrencia de los síntomas. También se presenta una revisión de los casos publicados.


Abstract Infection is a rare complication of abdominal aortic aneurysms. Campylobacter fetus has special tropism for vascular endothelium. It has been reported as a cause of infected abdominal aortic aneurysms. The mortality of these patients is high, so an early recognition with a start of antibiotic therapy is crucial. In addition to medical treatment surgery may be required, which has high mortality in patients with many diseases and unstable. We report the case of an old man with infected abdominal aortic aneurysm with C. fetus, whom was decided to be treated with imipenem, due to his cardiovascular history and his general condition at admission. The patient showed a good clinical response without recurrence of symptoms. We also carry out a review of the reported cases.


Asunto(s)
Humanos , Masculino , Anciano , Aneurisma Infectado/diagnóstico por imagen , Infecciones por Campylobacter/diagnóstico , Infecciones por Campylobacter/tratamiento farmacológico , Aneurisma de la Aorta Abdominal , Campylobacter fetus , Antibacterianos/uso terapéutico
10.
J Infect Chemother ; 27(7): 1080-1083, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-33563526

RESUMEN

Campylobacter jejuni and Campylobacter coli are the leading causes of bacterial intestinal infections worldwide, while Campylobacter fetus subsp. fetus (C. fetus) has been reported to cause extraintestinal infections, including medical device implant infections. However, breast implant infections have rarely been reported. We describe the case of a 64-year-old woman with breast implant infection and vertebral osteomyelitis due to C. fetus. The patient recovered by surgical removal of the infected left implant and was treated with antibiotics for 6 weeks. However, two weeks after the completion of antibiotics, she experienced an infection in the right implant due to C. fetus, which had developed quinolone resistance with a G91T mutation during the treatment course. This case showed that C. fetus can cause breast implant infections, and although the infection may appear to be unilateral initially, the possibility of sequential contralateral infection should be considered.


Asunto(s)
Implantes de Mama , Infecciones por Campylobacter , Campylobacter , Implantes de Mama/efectos adversos , Infecciones por Campylobacter/diagnóstico , Infecciones por Campylobacter/tratamiento farmacológico , Campylobacter fetus/genética , Femenino , Humanos , Persona de Mediana Edad
11.
Int J Food Microbiol ; 341: 109074, 2021 Mar 02.
Artículo en Inglés | MEDLINE | ID: mdl-33508583

RESUMEN

Campylobacter jejuni (C. jejuni) is one of the most common foodborne pathogens that cause human sickness mostly through the poultry food chain. Cinnamon essential oil (CEO) has excellent antibacterial ability against C. jejuni growth. This study investigated the antibacterial mechanism of CEO against C. jejuni primarily through metabolism, energy metabolism of essential enzymes (AKPase, ß-galactosidase, and ATPase), and respiration metabolism. Results showed that the hexose monophosphate pathway (HMP) was inhibited, and that the enzyme activity of G6DPH substantially decreased upon treatment with CEO. Analysis of the effect of CEO on the expression of toxic genes was performed by the real-time PCR (RT-PCR). The expression levels of the toxic genes cadF, ciaB, fliA, and racR under CEO treatment were determined. Casein/CEO nanospheres were further prepared for the effective inhibition of C. jejuni and characterized by particle-size distribution, zeta-potential distribution, fluorescence, TEM, and GC-MS methods. Finally, the efficiency of CEO and casein/CEO nanospheres in terms of antibacterial activity against C. jejuni was verified. The casein/CEO nanospheres displayed high antibacterial activity on duck samples. The population of the test group decreased from 4.30 logCFU/g to 0.86 logCFU/g and 4.30 logCFU/g to 2.46 logCFU/g at 4 °C and at 25 °C for C. jejuni, respectively. Sensory evaluation and texture analysis were also conducted on various duck samples.


Asunto(s)
Antibacterianos/farmacología , Infecciones por Campylobacter/veterinaria , Campylobacter jejuni/efectos de los fármacos , Caseínas/farmacología , Cinnamomum zeylanicum/química , Aceites Volátiles/farmacología , Animales , Infecciones por Campylobacter/tratamiento farmacológico , Pollos/microbiología , Preparaciones de Acción Retardada/farmacología , Patos/microbiología , Metabolismo Energético/efectos de los fármacos , Enfermedades Transmitidas por los Alimentos/microbiología , Enfermedades Transmitidas por los Alimentos/prevención & control , Expresión Génica/efectos de los fármacos , Glucosafosfato Deshidrogenasa/antagonistas & inhibidores , Humanos , Nanosferas , Vía de Pentosa Fosfato/efectos de los fármacos , Aves de Corral/microbiología
12.
Can Vet J ; 61(12): 1307-1311, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-33299249

RESUMEN

A 12-year-old Warmblood mare was referred for evaluation of behavioral changes not explained by general physical examination or lameness evaluation. Transrectal ultrasound examination was performed to determine if the behavioral changes were related to ovarian abnormalities, and a large abscess was found near the base of the cecum. Laparoscopic-guided aspiration and lavage of the abscess cavity followed by injection of benzyl penicillin G was carried out. Culture of the lavage sample yielded Campylobacter fetus subspecies fetus, an organism not previously reported as an etiological agent in abdominal abscesses in horses. The mare was treated after surgery with an extended course of antibiotics (minocycline per os q12h for 10 days followed by enrofloxacin per os q24h for 42 days). The mare resumed work in competitive eventing 10 months after surgery, and the behavioral complaints had resolved according to the owner. Key clinical message: We describe the diagnosis and treatment of a mare with an abdominal abscess from which Campylobacter fetus subspecies fetus was cultured. This organism has not previously been reported as an etiological agent in abdominal abscesses in horses.


Isolement de Campylobacter fetus sous-espèce fetus d'un abcès abdominal chez une jument adulte. Une jument Warmblood âgée de 12 ans fut référée pour évaluation de changements de comportement non-expliqués par un examen physique général ou une évaluation de boiterie. Un examen échographique transrectal fut effectué afin de déterminer si les changements de comportement étaient reliées à des anomales ovariennes et un large abcès fut trouvé près de la base du caecum. Une aspiration guidée par laparoscopie et un lavage de la cavité de l'abcès suivis d'une injection de benzyle pénicilline G furent effectués. Une culture de l'échantillon de lavage permis d'identifier Campylobacter fetus sous-espèce fetus, un organisme n'ayant pas été rapporté antérieurement comme agent étiologique dans les abcès abdominaux chez les chevaux. La jument fut traitée après la chirurgie avec un régime prolongé d'antibiotiques (minocycline per os q12h pour 10 jours suivi d'enrofloxacine per os q24h pour 42 jours). La jument recommença à travailler dans des compétitions 10 mois après la chirurgie et les plaintes concernant le comportement étaient résolues selon le propriétaire.Message clinique clé:Nous décrivons le diagnostic et le traitement d'une jument avec un abcès abdominal à partir duquel on isola C. fetus sous-espèce fetus. Cet organisme n'a pas été rapporté antérieurement comme agent étiologique dans les abcès abdominaux chez les chevaux.(Traduit par Dr Serge Messier).


Asunto(s)
Absceso Abdominal , Infecciones por Campylobacter , Campylobacter , Enfermedades de los Caballos , Absceso Abdominal/tratamiento farmacológico , Absceso Abdominal/veterinaria , Animales , Infecciones por Campylobacter/diagnóstico , Infecciones por Campylobacter/tratamiento farmacológico , Infecciones por Campylobacter/veterinaria , Campylobacter fetus , Femenino , Feto , Enfermedades de los Caballos/diagnóstico , Enfermedades de los Caballos/tratamiento farmacológico , Caballos
13.
J Immunother Cancer ; 8(2)2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-33020237

RESUMEN

Five patients receiving checkpoint inhibitor immunotherapy (CPI) under our care across two cancer centers over a 12-month period have subsequently developed campylobacterosis. All had received immune-suppressive treatment for CPI-related colitis in the weeks or months preceding the detection of Campylobacter infection, with negative stool cultures at presentation of CPI-related colitis. The immune-suppression required to treat CPI-related toxicity may lead to an increased risk of enteric infection within the gut. While the underlying immune and biologic mechanisms are not well understood, perturbation of the gut microbiota is an increasingly recognized factor capable of influencing CPI-mediated immune reconstitution and response to therapy. Clinicians should be aware that worsening of colitic symptoms in patients with a history of treatment for CPI-related colitis may be due to enteric infection, and not simply a relapse/deterioration of a previously treated CPI-related colitis. Judicious infectious disease evaluation is necessary for patients receiving CPIs as symptoms can mimic immune-related adverse events (irAEs). Furthermore, the benefits of immune-suppressive therapy for the treatment of presumptive irAEs must be weighed against the possible increased risk for either enteric infection or opportunistic infection. Prospective studies are required to investigate microbiome perturbations, resulting from immune-suppression, and guide future treatment of this patient cohort.


Asunto(s)
Infecciones por Campylobacter/tratamiento farmacológico , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Terapia de Inmunosupresión/métodos , Inmunoterapia/métodos , Humanos , Inhibidores de Puntos de Control Inmunológico/farmacología
14.
Infection ; 48(3): 471-475, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32128685

RESUMEN

BACKGROUND: While Campylobacter jejuni represents the most common cause of bacterial gastroenteritis, Yersinia pseudotuberculosis infections are very rarely diagnosed in adults. CASE: We report on a previously healthy patient who presented several times at our hospital with fever, Guillain-Barré syndrome, recurrent abdominal symptoms and distinct mesenteric lymphadenopathy, respectively. This complicated and diagnostically challenging course of disease was caused by a C. jejuni and Y. pseudotuberculosis coinfection. Antibiotic treatment with doxycycline was effective. CONCLUSION: Broad serology testing was crucial to discover that two concomitant infections were causing the symptoms. This case demonstrates that when a clinical picture is not fully explained by one known infection, another infection with the same underlying risk factor has to be considered, hence "a horse and a zebra".


Asunto(s)
Infecciones por Campylobacter/diagnóstico , Coinfección/diagnóstico , Enfermedades Gastrointestinales/diagnóstico , Síndrome de Guillain-Barré/diagnóstico , Infecciones por Yersinia pseudotuberculosis/diagnóstico , Adulto , Antibacterianos/uso terapéutico , Infecciones por Campylobacter/diagnóstico por imagen , Infecciones por Campylobacter/tratamiento farmacológico , Infecciones por Campylobacter/microbiología , Campylobacter jejuni/aislamiento & purificación , Coinfección/diagnóstico por imagen , Coinfección/tratamiento farmacológico , Coinfección/microbiología , Doxiciclina/uso terapéutico , Fiebre/microbiología , Enfermedades Gastrointestinales/diagnóstico por imagen , Enfermedades Gastrointestinales/tratamiento farmacológico , Enfermedades Gastrointestinales/microbiología , Alemania , Síndrome de Guillain-Barré/diagnóstico por imagen , Síndrome de Guillain-Barré/microbiología , Humanos , Linfadenopatía/diagnóstico , Linfadenopatía/microbiología , Masculino , Recurrencia , Resultado del Tratamiento , Yersinia pseudotuberculosis/aislamiento & purificación , Infecciones por Yersinia pseudotuberculosis/diagnóstico por imagen , Infecciones por Yersinia pseudotuberculosis/tratamiento farmacológico , Infecciones por Yersinia pseudotuberculosis/microbiología
15.
BMC Infect Dis ; 20(1): 199, 2020 Mar 06.
Artículo en Inglés | MEDLINE | ID: mdl-32143636

RESUMEN

BACKGROUND: Campylobacter jejuni is a motile, gram-negative rod known for causing self-limiting enterocolitis while rarely causing extraintestinal infections. We report the first case of a patient with Campylobacter jejuni osteomyelitis in both femora. CASE PRESENTATION: A 54-year-old female presented with progressive pain in both upper extremities. Her past medical history mentioned a lymphoplasmacytic lymphoma (LPL) for which she had received dexamethasone, cyclophosphamide and fludarabine and was still receiving maintenance therapy with intravenous rituximab. Two months prior to presentation, she received oral fluoroquinolone for a recurrent enterocolitis with stool cultures positive for Campylobacter jejuni. Palpation of the left quadriceps femoris muscle was remarkably painful during physical examination. Laboratory testing showed elevated C-reactive protein and recent low gamma globulin levels. The presumptive diagnosis at this point was a transformation of LPL to a large B cell lymphoma. In order to determine the preferred site for biopsy, a fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography combined with computed tomography was done. However, blood cultures taken on admission showed growth of Campylobacter jejuni in both aerobic bottles, with a strain resistant to fluoroquinolones. Diagnosis of Campylobacter jejuni osteomyelitis was confirmed with 16S ribosomal RNA gene polymerase chain reaction performed on femoral bone obtained through biopsy. Treatment with intravenous imipenem/cilastatin followed by intravenous and oral doxycycline proved insufficient. Subsequently, the patient was treated successfully with intravenous meropenem for six weeks and concurrent intravenous immunoglobulin. CONCLUSION: We report the first case of Campylobacter jejuni osteomyelitis in both femora in a patient with acquired hypogammaglobulinemia. Diagnosis was confirmed by blood cultures and positive 16S ribosomal RNA gene polymerase chain reaction for Campylobacter spp. on bone biopsy. Treatment was successful with intravenous meropenem and immunoglobulin. Our report showcases an unusual manifestation in a patient with immunodeficiency and discusses failure of initial antibiotic therapy.


Asunto(s)
Infecciones por Campylobacter/diagnóstico , Inmunodeficiencia Variable Común/diagnóstico , Osteomielitis/diagnóstico , Antibacterianos/uso terapéutico , Proteína C-Reactiva/análisis , Infecciones por Campylobacter/complicaciones , Infecciones por Campylobacter/tratamiento farmacológico , Infecciones por Campylobacter/microbiología , Campylobacter jejuni/genética , Campylobacter jejuni/aislamiento & purificación , Inmunodeficiencia Variable Común/complicaciones , Doxiciclina/uso terapéutico , Femenino , Fémur/efectos de los fármacos , Humanos , Persona de Mediana Edad , Osteomielitis/complicaciones , Osteomielitis/tratamiento farmacológico , Osteomielitis/microbiología , Tomografía Computarizada por Tomografía de Emisión de Positrones , ARN Ribosómico 16S/genética , ARN Ribosómico 16S/metabolismo
16.
J Gastrointest Cancer ; 51(3): 824-828, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-31482407

RESUMEN

OBJECTIVE: Antimicrobial properties of silymarin and curcumin have been assessed against several infectious agents. The aim of this study was to investigate the anti-apoptotic and antibacterial effects of both compounds on the expression of genes among Shigella dysenteriae ATCC 12022 and Campylobacter jejuni subsp. jejuni strain ATCC 33560 standard strains. METHODS: S. dysenteriae and C. jejuni standard strains were prepared from reference laboratory. Additionally, two clinical multidrug-resistant (MDR) isolates were adopted. Silymarin and curcumin stocks were purchased from Sigma Corporation (USA), and after preparation of dilutions (0.5-512 µg/ml), the minimum inhibitory concentration (MIC) and minimum bactericidal concentrations (MBC) were determined. Furthermore, the effect of 100 µg/ml of each compound was also evaluated on the expression of two gyrB and 16S rRNA housekeeping genes by quantitative real-time PCR (qRT-PCR). RESULTS: Silymarin MIC and MBC were 512 µg/ml and > 512 µg/ml against S. dysenteriae and > 512µg/ml against C. jejuni standard strains, respectively. Moreover, curcumin MIC and MBC concentrations were 256 µg/ml and 512 µg/ml, respectively for ATCC strains. Silymarin down-expressed the expression of gyrB gene in S. dysenteriae and gyrB and 16srRNA gene in C. jejuni significantly (p < 0.05) compared with unexposed strains. In addition, curcumin could down-express the both gyrB and 16S rRNA genes in both strains significantly (p < 0.05). For two MDR clinical isolates, both MIC and MBC of compounds were > 512 µg/ml. Addition of 100 µg/ml curcumin and silymarin to ampicillin (10 µg/ml) lowered the MIC of MDR S. dysenteriae to 256 µg/ml and 512 µg/ml, respectively. However, no MIC change was observed with regard to C. jejuni. CONCLUSION: In this study, curcumin and silymarin could inhibit the growth of S. dysenteriae and C. jejuni and 100 µg/ml sub-MIC levels exhibited the suppression of housekeeping genes. Combating pathogenic bacteria by compounds alternative to antibiotics in the era of antibiotic resistance is a proper strategy, though more studies using combinations of them are needed.


Asunto(s)
Campylobacter/efectos de los fármacos , Curcumina/farmacología , Shigella dysenteriae/efectos de los fármacos , Silimarina/farmacología , Ampicilina/farmacología , Ampicilina/uso terapéutico , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Campylobacter/genética , Infecciones por Campylobacter/tratamiento farmacológico , Infecciones por Campylobacter/microbiología , Curcumina/uso terapéutico , Girasa de ADN/genética , ADN Bacteriano/aislamiento & purificación , Regulación hacia Abajo/efectos de los fármacos , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Farmacorresistencia Bacteriana Múltiple/genética , Quimioterapia Combinada/métodos , Disentería Bacilar/tratamiento farmacológico , Disentería Bacilar/microbiología , Regulación Bacteriana de la Expresión Génica/efectos de los fármacos , Genes Esenciales , Humanos , Pruebas de Sensibilidad Microbiana , ARN Ribosómico 16S/genética , Shigella dysenteriae/genética , Silimarina/uso terapéutico
17.
Pathol Int ; 69(10): 572-579, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31631463

RESUMEN

Castleman-Kojima disease, also known as idiopathic multicentric Castleman disease with TAFRO syndrome (iMCD-TAFRO), is a recently recognized systemic inflammatory disorder with a characteristic series of clinical symptoms, including thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly (O). Patients with iMCD-TAFRO often develop severe abdominal pain, elevated alkaline phosphatase levels, and systemic inflammation, but the etiological factors are unknown. To investigate the potential role of bacterial infection in the pathogenesis of iMCD-TAFRO, we performed polymerase chain reaction (PCR) for the bacterial 16S rRNA gene with DNA extracted from liver specimens of three patients with iMCD-TAFRO, four patients with amyotrophic lateral sclerosis, and seven patients with inflammatory conditions. Sequencing of the PCR product showed 99% DNA sequence identity with Campylobacter jejuni in all three patients with iMCD-TAFRO and in two patients with inflammatory conditions. Immunohistochemical and electron microscopy analyses could not identify C. jejuni in patients with iMCD-TAFRO. The findings indicated that C. jejuni infection is not the pathological cause of iMCD-TAFRO; however, this ubiquitous bacterium may play a role in uncontrolled systemic hypercytokinemia, possibly through the development of cross-reactive autoantibodies.


Asunto(s)
Infecciones por Campylobacter/tratamiento farmacológico , Campylobacter jejuni/patogenicidad , Enfermedad de Castleman/patología , Reticulina/farmacología , Anciano , Anciano de 80 o más Años , Campylobacter jejuni/efectos de los fármacos , Enfermedad de Castleman/tratamiento farmacológico , Enfermedad de Castleman/microbiología , Femenino , Fiebre/diagnóstico , Humanos , Inflamación/tratamiento farmacológico , Inflamación/microbiología , Inflamación/patología , Hígado/efectos de los fármacos , Hígado/microbiología , Hígado/patología , Masculino , Persona de Mediana Edad , Insuficiencia Renal/tratamiento farmacológico , Trombocitopenia/microbiología , Trombocitopenia/patología
18.
Rev. chil. infectol ; 36(5): 663-666, oct. 2019. tab
Artículo en Español | LILACS | ID: biblio-1058093

RESUMEN

Resumen La bacteriemia es una presentación atípica de la infección por Campylobacter jejuni, y es más frecuente en pacientes con inmunodepresión avanzada debido al VIH u otras enfermedades sistémicas. Debido a la terapia anti-retroviral, en las últimas décadas el número de casos ha disminuido. Presentamos el caso de una mujer en situación de calle, con VIH en etapa C3, que cursó con una bacteriemia por C. jejuni durante su hospitalización por una tuberculosis pulmonar. Realizamos una breve revisión de bacteriemia por C. jejuni en pacientes con VIH.


Bacteremia is an atypical presentation of Campylobacter jejuni infection and it is more frequent in patients with advanced inmunodepression due to HIV or other sistemic diseases. Because of the highly active antiretroviral therapy, in the last decades the number of cases had declined. We report a case of a homeless woman with HIV in C3 stage who was diagnosed with the bacteremia during her hospitalization for pulmonary tuberculosis, and a brief review of C. jejuni bacteremia in HIV patients.


Asunto(s)
Humanos , Femenino , Adulto , Infecciones por Campylobacter/microbiología , Campylobacter jejuni/aislamiento & purificación , Bacteriemia/microbiología , Infecciones Oportunistas Relacionadas con el SIDA/microbiología , Tuberculosis Pulmonar/tratamiento farmacológico , Infecciones por Campylobacter/inmunología , Infecciones por Campylobacter/tratamiento farmacológico , Bacteriemia/inmunología , Bacteriemia/tratamiento farmacológico , Infecciones Oportunistas Relacionadas con el SIDA/inmunología , Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Antibacterianos/uso terapéutico
19.
Rev Med Liege ; 74(7-8): 420-423, 2019 Jul.
Artículo en Francés | MEDLINE | ID: mdl-31373458

RESUMEN

Cases of Campylobacter jejuni meningitis are extremely rare. In the literature, less than ten cases have been described so far, although Campylobacter spp is one of the most common pathogens causing gastroenteritis in the world. Some common stigmata can be found across these cases such as rupture of the blood-brain barrier, immunosuppression, as well as the tropism of Camplylobacter jejuni for neurological parenchyma. Campylobacter jejuni bacteremia is certainly underestimated because Campylobacter is a thermophilic bacterium and special conditions are required to isolate this organism in blood cultures. PCR is thus an interesting alternative technique for diagnosis. In our case, a patient with a history of resected astrocytoma, had undergone treatment with chemotherapy and radiotherapy because of anaplastic transformation. The patient was admitted with gastroenteritis and Campylobacter jejuni meningitis. The diagnosis was obtained initially on stool cultures and then by PCR of cerebrospinal fluid. The evolution was favorable with meropenem.


Les cas de méningite à Campylobacter jejuni restent extrêmement rares. Dans la littérature, on décrit moins de 10 cas à ce jour, alors que l'infection à Campylobacter est cependant l'une des causes les plus répandues de gastro-entérite dans le monde. Le point commun de tous ces cas de méningite rapportés semble être la fragilité de la barrière hémato-encéphalique et l'immunodépression, ainsi que le tropisme du Campylobacter jejuni pour les tissus neuronaux. La bactériémie à Campylobacter jejuni est par ailleurs sous-estimée car le germe est thermophilique et des conditions particulières sont nécessaires pour isoler cet organisme dans les hémocultures. La PCR est une alternative intéressante pour le diagnostic microbiologique. Dans le cas décrit, le patient présentait des antécédents d'astrocytome pariéto-temporal droit opéré, avec une transformation anaplasique ayant bénéficié de chimio- et radiothérapie concomitantes. Le patient a été admis avec une gastro-entérite compliquée d'une méningite à Campylobacter jejuni. Le diagnostic a été posé initialement sur la coproculture et ensuite par la PCR du liquide céphalo-rachidien. L'évolution a été favorable sous méropénem.


Asunto(s)
Infecciones por Campylobacter , Campylobacter jejuni , Meningitis , Infecciones por Campylobacter/diagnóstico , Infecciones por Campylobacter/tratamiento farmacológico , Campylobacter jejuni/genética , Humanos , Meropenem , Reacción en Cadena de la Polimerasa
20.
Transpl Infect Dis ; 21(1): e13021, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30403433

RESUMEN

BACKGROUND: Guillain-Barré syndrome (GBS) is a common ascending polyneuropathy in adults. It is often associated with preceding viral or diarrhoeal illness with cytomegalovirus (CMV), Epstein-Barr virus (EBV), or Campylobacter jejuni. Solid organ transplant recipients are more susceptible to opportunistic infections with CMV than the general population as a result of immunosuppressive therapies to prevent graft rejection. However, reports of GBS are rare in this population. OBJECTIVE: To systematically review cases of GBS in renal transplant patients to evaluate causative pathogens or triggers, management and associated morbidity and mortality. METHODS AND RESULTS: We conducted a systematic search of the MEDLINE database uncovering 17 cases of GBS in renal transplant patients in the literature. The majority of cases were in males (81%) and patients who received deceased donor renal transplants (87%). The mean age was 44.7 years (SD 13). The time between transplant and onset of symptoms ranged from 2 days to 10 years (Mean = 720 days). GBS was commonly associated with antecedent viral (CMV 12; EBV 1) or diarrhoeal (2) illness while two cases were attributed to calcineurin inhibitor use. All patients recovered fully or partially after treatment with anti-viral or anti-bacterial agents, immunoglobulins, and/or plasma exchange. CONCLUSION: Cytomegalovirus is the most common trigger for GBS in the post-renal transplant setting. Other triggers include campylobacter jejuni and calcineurin inhibitors. GBS should be considered in transplant patients presenting with weakness or paralysis in order to institute timely management.


Asunto(s)
Infecciones por Campylobacter/epidemiología , Infecciones por Citomegalovirus/epidemiología , Diarrea/epidemiología , Infecciones por Virus de Epstein-Barr/epidemiología , Síndrome de Guillain-Barré/epidemiología , Trasplante de Riñón/efectos adversos , Antibacterianos/uso terapéutico , Antivirales/uso terapéutico , Inhibidores de la Calcineurina/efectos adversos , Infecciones por Campylobacter/tratamiento farmacológico , Infecciones por Campylobacter/microbiología , Campylobacter jejuni/aislamiento & purificación , Citomegalovirus/aislamiento & purificación , Infecciones por Citomegalovirus/tratamiento farmacológico , Infecciones por Citomegalovirus/virología , Diarrea/tratamiento farmacológico , Diarrea/microbiología , Infecciones por Virus de Epstein-Barr/tratamiento farmacológico , Infecciones por Virus de Epstein-Barr/virología , Síndrome de Guillain-Barré/tratamiento farmacológico , Síndrome de Guillain-Barré/etiología , Herpesvirus Humano 4/aislamiento & purificación , Humanos , Incidencia , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA